Physician profile
David Kau
NPI 1063702405
$2,293.57
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.18 · 2021: $208 · 2022: $640 · 2023: $1,044 · 2024: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.04 |
| Education | $134.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $611.19 | 2021-2024 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $291.19 | 2021-2024 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $265.28 | 2021-2024 | |
| Calliditas Therapeutics US INC. | $169.15 | 2022-2024 | Tarpeyo |
| Travere Therapeutics, INC. | $127.48 | 2023-2024 | |
| Abbvie INC. | $125.80 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $110.48 | 2021-2023 | Jynarque |
| Vifor Pharma, INC. | $81.25 | 2021-2023 | Veltassa |
| Opko Pharmaceuticals, LLC | $65.62 | 2023 | Rayaldee |
| Horizon Therapeutics Plc | $62.93 | 2023 | Krystexxa |
| Fresenius USA Marketing, INC. | $53.42 | 2021-2024 | Velphoro |
| Amarin Pharma, INC. | $38.71 | 2021 | |
| Glaxosmithkline, LLC. | $38.03 | 2022-2023 | Jesduvroq |
| Ardelyx, INC. | $35.79 | 2023-2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.17 | 2023 | Jardiance, Synjardy, Tradjenta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $24.28 | 2023 | Xarelto |
| Kyowa Kirin, INC. | $23.76 | 2024 | Crysvita |
| Noven Therapeutics, LLC | $22.18 | 2020 | |
| Axonics, INC. | $21.26 | 2023 | Bulkamid, Axonics |
| Lilly USA, LLC | $20.30 | 2023 | Jardiance |
| Alexion Pharmaceuticals, INC. | $19.14 | 2023 | Ultomiris |
| Myriad Genetic Laboratories, INC. | $17.70 | 2024 | Prolaris |
| Amgen INC. | $17.58 | 2024 | Tavneos |
| Biomerieux INC | $16.88 | 2023 | Biofire Blood Culture Identification 2 (Bcid2) Panel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.